Prostate-specific antigen after cryosurgical ablation of the prostate. Defining the appropriate response

Urol Clin North Am. 1997 May;24(2):415-20. doi: 10.1016/s0094-0143(05)70388-8.

Abstract

The ability of prostate-specific antigen (PSA) to predict long-term cure after cryotherapy for localized prostate cancer is not known because experience with this treatment modality is limited; however, it appears that a PSA value of 0.5 ng/mL or less at 6 months or longer after cryotherapy is associated with a high probability of a negative post-treatment biopsy (greater than 95%). An undetectable PSA (less than 0.1 ng/mL) 3 months after the procedure is associated with a likelihood of a negative biopsy at 6 months and low, stable PSA levels up to 2 years.

MeSH terms

  • Biopsy
  • Cryosurgery*
  • Humans
  • Male
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery*
  • Sensitivity and Specificity

Substances

  • Prostate-Specific Antigen